Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health


Personal tools

You are here: Home / Biomarkers / ADH5



This biomarker is also known as:
  • S-(hydroxymethyl)glutathione dehydrogenase,
  • FALDH,
  • alcohol dehydrogenase class-III,
  • Glutathione-dependent formaldehyde dehydrogenase,
  • ADHX,
  • Alcohol dehydrogenase class chi chain,
  • alcohol dehydrogenase class chi chain,
  • alcohol dehydrogenase (class III), chi polypeptide,
  • GSH-FDH,
  • GSNOR,
  • formaldehyde dehydrogenase,
  • Alcohol dehydrogenase class-III,
  • glutathione-dependent formaldehyde dehydrogenase,
  • alcohol dehydrogenase class-3,
  • FDH,
  • ADH-3,
  • Alcohol dehydrogenase 5,
  • alcohol dehydrogenase 5 (class III), chi polypeptide,
  • EC,EC 1.1.1.-,EC,

View in BioMuta


ADH5 is a member of the alcohol dehydrogenase family. This protein forms a homodimer. ADH5 is ineffective in oxidizing ethanol, but exhibits high activity for oxidation of long-chain primary alcohols and for oxidation of S-hydroxymethyl-glutathione, a spontaneous adduct between formaldehyde and glutathione. There are several non-transcribed pseuodogenes related to this gene.


QA State: Curated
Type: Protein
Short Name:


There are no datasets associated with this biomarker.


The following organs have data associated with this biomarker…



Phase: Two
QA State: Under Review


No additional breast data available.

Performance Comment

ADH5 was one of numerous potential early detection biomarkers specific to triple-negative breast cancer in multiple pathways identified.


This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at if you should have access to this biomarker.

2015 EDRN PI Orientation

The New and Continuing EDRN Principal Investigator Orientation will take place January 20–21, 2016 in Bethesda, Maryland.

Announcement 08/26/2015

Thank you to everyone who made the 29th EDRN Steering Committee Meeting a success. The orientation for new and continuing EDRN PIs will be held Wednesday-Thursday, January 20-21, 2016, on the NCI campus. More information will be available later this summer.

Announcement 06/30/2015

A funding opportunity for a new pancreatic cancer initiative, called The Pancreatic Cancer Detection Consortium (U01), has been released. For more information, please go to /grants/guide/ pa-files/ PAR-15-289.html.